Skip to content
Visnia
CtrlK
EconomyAI buildoutMarket MapFundsWatchlist
Log in
Market cap
Revenue
Net income
Cash on hand
Gross margin
Net margin
EPS
P/E ratio
Search
Market mapFundsWatchlist
Visnia

CChemomab Therapeutics Ltd.

EconomyAI buildoutMarket MapFundsWatchlist
Log in
C

Chemomab Therapeutics Ltd.

$1.39Close · Oct 8, 2026
  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Similar companies
  • News
  • Insider Transactions
Loading financials
Fiscal Q2 2026Jun 30, 2026
Fiscal Q2 2025Jun 30, 2025
Fiscal Q2 2024Jun 30, 2024
Fiscal Q2 2023Jun 30, 2023
Fiscal Q1 2023Mar 31, 2023
Fiscal Q4 2022Dec 31, 2022
The costs of running the business beyond making or delivering its products, such as research, marketing, and office expenses.
-0.9% YoY-40.0% YoY-54.0% YoY+31.0% YoY+70.1% YoY+72.0% YoY
Profit before income taxes are taken out.Formula: Operating income + net non-operating income + pre-tax adjustments
-5.3% YoY+43.3% YoY+54.2% YoY-17.8% YoY-71.1% YoY-64.1% YoY
The income tax cost counted against the period’s profit, including amounts payable now or later.
The profit left after all expenses and taxes. A negative number means the company lost money.Formula: Total income − total expenses
-5.3% YoY+43.3% YoY+54.4% YoY-28.8% YoY-71.5% YoY-64.3% YoY
Profit for each ordinary share during the reporting period.Formula: Earnings available to common shareholders ÷ weighted-average basic shares
-25.0% YoY-69.2% YoY-63.9% YoY+33.3% YoY+81.8% YoY-100.0% YoY
Profit per share after counting potential extra shares from stock awards or convertible securities that would reduce it.Formula: Diluted earnings available to common shareholders ÷ weighted-average diluted shares
-25.0% YoY-69.2% YoY-63.9% YoY+33.3% YoY+81.8% YoY-100.0% YoY